BE

HeartBeam, Inc.

BEATHealthcareNASDAQ

Health Information Services

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$0
Net Income
-$21.0M
-8.1% YoY
EBITDA
-$21.1M
-6.1% YoY
Free Cash Flow
-$6.6M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.0002, negative momentum
RSI OversoldRSI 20.1, below 30, stock may be oversold
Sep 2 RSI OversoldRSI 26.3, below 30, stock may be oversold
About HeartBeam, Inc.

HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare. The $25.1M market capitalization puts BEAT squarely in micro-cap range for its industry. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms.

Where BEAT stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, BEAT finished 51.09% below its 150-day moving average ($0.92) and 61.21% below its 200-day moving average ($1.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is BEAT overbought or oversold?

At the September 3, 2026 close, BEAT's RSI(14) was 20.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$25.1M
Fwd P/E-0.84
EPS$-0.51
Beta-0.80
52W Change-68.8%
ROE-328.4%
Analysis

HeartBeam, Inc. reports $8.7M in cash and $0 in total debt. Free cash flow is running at -$6.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -328.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.

The relatively low beta of -0.80 suggests BEAT is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for HeartBeam, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms